Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
18 Março 2024 - 8:15AM
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a
developmental stage biopharmaceutical company focused on developing
novel formulations and drug delivery systems for traditional
therapeutics and psychedelic treatments, today announced that it
has filed a provisional patent application titled ‘Methods and
Combinations for Managing Pain’ with the United States Patent and
Trademark Office (USPTO).
The patent application includes protection
for the Company’s SP-26 implantable drug delivery system for a
novel time-released, dose-controlled formulation of ketamine,
initially targeted for fibromyalgia. Silo believes that
implantable drug delivery may be well-suited for chronic pain
management.
“Our SP-26 implant technology is designed to deliver a steady,
low dose of ketamine for sustained relief of chronic pain,” said
Eric Weisblum, CEO of Silo. “We are pleased with the implant’s
performance in pre-clinical studies to date. If approved, SP-26
could be the first at-home approved ketamine based
therapeutic.”
The next tests of the SP-26 ketamine implant will measure
drug dissolution and time-release action.
About SP-26
Silo’s SP-26 is a ketamine-based injectable dissolvable implant
for the treatment of chronic pain and fibromyalgia. The
subcutaneous implant is being designed to safely regulate dosage
and time release, of the pain-relieving treatment. If clinically
successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2)
regulatory pathway for drug approval.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage
biopharmaceutical company developing novel therapeutics that
address underserved conditions including stress-induced psychiatric
disorders, chronic pain conditions, and central nervous system
(CNS) diseases. Silo focuses on developing traditional therapies
and psychedelic treatments in novel formulations and drug delivery
systems. The Company’s lead program, SPC-15, is an intranasal
treatment targeting PTSD and stress-induced anxiety disorders.
SP-26 is a time-release ketamine-loaded implant for fibromyalgia
and chronic pain relief. Silo’s two preclinical programs are
SPC-14, an intranasal compound for the treatment of Alzheimer’s
disease, and SPU-16, a CNS-homing peptide targeting multiple
sclerosis (MS). Silo’s research and development programs are
conducted through collaborations with Columbia University and the
University of Maryland, Baltimore. For more information, visit
www.silopharma.com and connect on social media at LinkedIn, X, and
Facebook.
Forward-Looking
Statements
This news release contains "forward-looking statements" within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
identified by the use of words “could”, “believe”, “anticipate”,
“intend”, “estimate”, “expect”, “may”, “continue”, “predict”,
“potential”, and similar expressions that are intended to identify
forward-looking statements. Such statements involve known and
unknown risks, uncertainties, and other factors that could cause
the actual results of Silo Pharma, Inc. (“Silo” or “the Company”)
to differ materially from the results expressed or implied by such
statements, including changes to anticipated sources of revenues,
future economic and competitive conditions, difficulties in
developing the Company’s technology platforms, retaining and
expanding the Company’s customer base, fluctuations in consumer
spending on the Company’s products and other factors. Accordingly,
although the Company believes that the expectations reflected in
such forward-looking statements are reasonable, there can be no
assurance that such expectations will prove to be correct. The
Company disclaims any obligations to publicly update or release any
revisions to the forward-looking information contained in this
presentation, whether as a result of new information, future
events, or otherwise, after the date of this presentation or to
reflect the occurrence of unanticipated events except as required
by law.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Silo Pharma (NASDAQ:SILO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024